Home > Community > Chemicals > Migami Continues Implementation of Acquisition Strategy regarding Various Proprietary Drug-Delivery Platforms and CMG Manufacturing Facilities

Migami Continues Implementation of Acquisition Strategy regarding Various Proprietary Drug-Delivery Platforms and CMG Manufacturing Facilities

Published: 30 Mar 2009 19:21:23 PST

Migami, Inc, a publicly traded pharmaceutical and cosmeceutical company (symbol: MIGA) located in Woodland Hills, CA, ("Migami") is negotiating a Letter of Intent ("LOI") regarding an Asset Purchase Agreement with respect to Migami's proposed acquisition of a patented, liposomal drug-delivery platform and certain related manufacturing assets. The liposomal drug-delivery platform being acquired is considered by many to be the next evolutionary step in liposomal technology.

This prospective purchase represents a vital component of Migami's strategic efforts concerning the acquiring of proprietary, drug-delivery systems that can be used to maximize the market potential for innovative cutting-edge drug-delivery systems. This proposed acquisition is the first in a planned series of acquisitions, which will provide Migami with a wide array of such proprietary, drug-delivery systems to offer to its customers, as well as CMG manufacturing capability. Although Migami's initial strategy emphasizes Asia, where Migami has an established network of industry partners, Migami's ultimate plan is to expand its operations to a worldwide basis.

The liposomal drug-delivery platform being acquired also appears to have wide potential application in the cosmetics field. Migami is also active in the Asian cosmetics market at present.